1. Home
  2. HIO vs ALLO Comparison

HIO vs ALLO Comparison

Compare HIO & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HIO
  • ALLO
  • Stock Information
  • Founded
  • HIO 1993
  • ALLO 2017
  • Country
  • HIO United States
  • ALLO United States
  • Employees
  • HIO N/A
  • ALLO N/A
  • Industry
  • HIO Finance/Investors Services
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • HIO Finance
  • ALLO Health Care
  • Exchange
  • HIO Nasdaq
  • ALLO Nasdaq
  • Market Cap
  • HIO 366.1M
  • ALLO 371.8M
  • IPO Year
  • HIO N/A
  • ALLO 2018
  • Fundamental
  • Price
  • HIO $3.89
  • ALLO $1.27
  • Analyst Decision
  • HIO
  • ALLO Strong Buy
  • Analyst Count
  • HIO 0
  • ALLO 9
  • Target Price
  • HIO N/A
  • ALLO $8.44
  • AVG Volume (30 Days)
  • HIO 305.3K
  • ALLO 4.2M
  • Earning Date
  • HIO 01-01-0001
  • ALLO 05-13-2025
  • Dividend Yield
  • HIO 10.33%
  • ALLO N/A
  • EPS Growth
  • HIO N/A
  • ALLO N/A
  • EPS
  • HIO N/A
  • ALLO N/A
  • Revenue
  • HIO N/A
  • ALLO N/A
  • Revenue This Year
  • HIO N/A
  • ALLO N/A
  • Revenue Next Year
  • HIO N/A
  • ALLO $10.02
  • P/E Ratio
  • HIO N/A
  • ALLO N/A
  • Revenue Growth
  • HIO N/A
  • ALLO N/A
  • 52 Week Low
  • HIO $3.52
  • ALLO $0.86
  • 52 Week High
  • HIO $4.03
  • ALLO $3.78
  • Technical
  • Relative Strength Index (RSI)
  • HIO 56.83
  • ALLO 51.48
  • Support Level
  • HIO $3.79
  • ALLO $1.10
  • Resistance Level
  • HIO $3.92
  • ALLO $1.15
  • Average True Range (ATR)
  • HIO 0.04
  • ALLO 0.11
  • MACD
  • HIO 0.00
  • ALLO 0.03
  • Stochastic Oscillator
  • HIO 76.92
  • ALLO 80.39

About HIO Western Asset High Income Opportunity Fund Inc.

Western Asset High Income Oppor Fd Inc is a diversified closed-end management investment company. The company's primary objective is to seek high current income and the secondary objective is capital appreciation. It invests a majority of its net assets in high-yield corporate debt securities and the rest in common stock equivalents, including options, warrants, and rights. The company invests in securities of companies from various sectors such as energy, technology, utilities, industrials, communications, finance, and capital goods among others.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Share on Social Networks: